A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. (Q33346173)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. |
scientific article |
Statements
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer (English)
Henry C Pitot
Grace K Dy
Alex A Adjei
Lorelei J Hanson
Charles Erlichman
Pamela J Atherton
Steven R Alberts
Joel M Reid
Richard M Goldberg
Tanya Watanabe
Richard S Geary
Jon Holmlund